<DOC>
	<DOCNO>NCT00417716</DOCNO>
	<brief_summary>Intravitreal Bevacizumab effective treatment diffuse diabetic macular edema</brief_summary>
	<brief_title>Use Intravitreal Bevacizumab Patients With Diffuse Diabetic Macular Edema</brief_title>
	<detailed_description>A non-randomized prospective clinical interventional study include 45 non previously treat patient DME . The patient receive single intravitreal injection 2.5 mg bevacizumab . Follow-up include clinical examination ( best correct visual acuity ( BCVA , intraocular pressure ( IOP ) , cataract grading , DME characteristic systemic check-up ) pre-injection , first visit , week 1 2 month 1 3 . OCT fluorescein angiography evaluated month 1 3 .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Type 2 diabetes Macular edema involve center macula demonstrate OCT Clear ocular medium Untreated patient Older 45 year BCVA fellow eye least 20/100 Renal diabetic disease , uncontrolled hypertension stroke history Other ocular disease Ocular surgery except uncomplicated phacoemulsification History photocoagulation ( panretinal focal ) History another intravitreal treatment ( like triamcinolone )</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2006</verification_date>
	<keyword>Diffuse Diabetic Macular Edema</keyword>
	<keyword>Intravitreal Bevacizumab</keyword>
	<keyword>Anti-VEGF drug</keyword>
</DOC>